Brief: Regulus Therapeutics Doses First Patient In Phase 1B Multiple-Ascending Dose Clinical Trial Of RGLS8429 For Treatment Of Autosomal Dominant Polycystic Kidney Disease

Regulus Therapeutics

02/11/2022 12:50

Nov 2 (Reuters) - Regulus Therapeutics Inc  RGLS.O :
    * REGULUS THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN
PHASE 1B
MULTIPLE-ASCENDING DOSE (MAD) CLINICAL TRIAL OF RGLS8429 FOR THE
TREATMENT OF AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE
(ADPKD)
    * REGULUS THERAPEUTICS INC- TOPLINE DATA FROM FIRST COHORT
OF
PATIENTS IS EXPECTED IN MID-2023

Source text for Eikon:  ID:nPn8GFDka 
Further company coverage:  RGLS.O 
 ((Reuters.Briefs@thomsonreuters.com;;))